Skip to content
Biotechnology, Property Real Estate

Mould Eradicated! Allied BioServices launches mould remediation service for residential property

Allied BioServices 2 mins read

Sydney 19 July 2023 In a ground-breaking first-to-market initiative, Allied BioServices has launched a revolutionary new mould remediation service which will see the business partner with residential property owners and managers to eliminate harmful mould from homes.

 

The service, which leverages a cutting-edge, long-lasting non-toxic coating technology, responds to the growing incidence of concern among tenants about mould in their homes and aims to eradicate it from residential rental properties.

 

Introducing the program, Allied BioServices’ Vice President, Strategic Partnerships, Dan Ode said, “Mould is a long-standing challenge across Australia, presenting health risks and compromising situations for both landlords and tenants.”

 

“Complaints and requests for elimination of chronic mould are a challenge for Property Managers, especially those with sizeable portfolios under management, particularly in tropical and sub-tropical areas. With the abundance of rain this winter, a warming climate, increased humidity, and more frequent extreme weather, this will only continue. Our service addresses these challenges in a safe and accessible way.”

 

“No Australian should have to live in a property infested with mould,” Mr Ode said, “and by applying our solution, they won’t need to.”

 

The service takes a systematic approach to eradicate mould from Australia’s public and private rental housing stock.

 

The solution is environmentally friendly, nontoxic, and clinically proven to make surfaces hostile to a large range of spores, germs, bacteria, viruses, and COVID-19. The long-lasting, TGA verified product is combined with a specialised surface preparation and application service leveraging state-of-the-art electrostatic sprayers and has been applied, independently tested and proven effective across a wide range of properties.

 

The coating is non-toxic so it is pet friendly and can be applied anytime during the duration of the lease as tenants don’t need to move out for the service to be undertaken.

 

Allied BioServices is taking expressions of interest from those who would like to learn more or book the service. Given the competitive price point and prevalence of damp mould conducive conditions across the east coast of Australia, the company has had strong demand in pre-launch testing of the market for the service.

 

The service is currently available to real estate businesses and property managers across all the Eastern seaboard including the ACT and Victoria.

 

 

ends

  

Interviews available

 

  • Allied BioServices Vice President, Strategic Partnerships, Dan Ode 

 

About Allied BioServices 

Allied BioServices is an Australian company operating across Australia and New Zealand. It provides the world’s best infection control technologies and services to prevent avoidable infection and protect people’s health. Allied BioServices’ technologies and services are guaranteed to deliver proven, high-quality outcomes that are sustainable and eco-friendly. Our technologies and services create safer spaces. 

https://alliedbioservices.com.au/


Key Facts:

Allied BioServices launches new mould remediation service for residential property.

Environmentally friendly, long lasting, non toxic solution that also makes surfaces hostile to spores, germs, bacteria and viruses, including COVID-19.

No need to vacate property for the service to be undertaken.

Available across Australia's Eastern seaboard.

Benefit to Property Managers:

• Protect landlord investment

• Protect tenants

• Decreased vacancy rates – due to clean / protected residence

• Gain increased market share due to unique offering

Benefit to Landlords:

• Protect investment — maintain rental value

• Protect property from serious mould issues

• If rental is fully furnished, protects home contents

• Protect property from further damage.

Benefit to Tenants:

• Minimise risk of mould-associated health issues

• Home is protected from further mould damage

• Are not exposed to highly toxic chemicals

• Pet friendly


Contact details:

Monika Lancucki, Pesel & Carr

Mob: 0413 440 236

Email: monika.lancucki@peselandcarr.com.au

 

More from this category

  • Government VIC, Property Real Estate
  • 18/10/2024
  • 06:00
CHIA Vic

Victorians urged to vote for council candidates committed to affordable housing

Victoria’s peak body for community housing is urging residents voting in this month’s council elections to back candidates who support building more affordable housing in their communities.Community Housing Industry Association Victoria encourages residents to vote for candidates who: Champion social housingand are willing to confront community opposition to new social and affordable housing initiatives Will discount or waive council rates for community housingwhich costs the sector an estimated $20-25 million every year across the state Support community housing organisations to build homes on surplus council landat peppercorn rent. CHIA Vic chief executive Sarah Toohey said:“While the state and federal governments…

  • Property Real Estate
  • 17/10/2024
  • 09:02
Highland

Local Buyer Purchasers $6.75MIL Property in Ozone Project, Months Before Development is Due to Complete

Soon to be completed, the recent removal of the scaffolding has unveiled the Ozone Project as the most premier apartment development in Cronulla. Testament…

  • Contains:
  • Biotechnology
  • 17/10/2024
  • 06:08
Dementia Australia

Rejection of drug a blow for Australians living with Alzheimer’s disease

Dementia Australia is disappointed by the initial decision of the Therapeutic Goods Administration (TGA) to reject Lecanemab for use in Australia. Lecanemab is a disease modifying treatment for people living with the early stages of Alzheimer’s disease or mild cognitive impairment. Developed by pharmaceutical company Eisai, Lecanemab works by removing amyloid plaques from the brain and in doing so slows cognitive decline associated with the disease. Lecanemab is currently approved for use in the UK, USA, Japan, China, South Korea, Hong Kong, United Arab Emirates and Israel. In July it was rejected by the European Medicines Agency, a decision that…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.